This study tests a new drug, **SRG-514**, given during breast cancer surgery. This is the first time it's being used in humans. The study aims to find the best dose for future research. The drug will be tested in small groups, starting with a low dose and increasing to see how safe it is. This process is called a **dose escalation trial**, where 3 to 6 patients try each dose, totaling about 12-18 participants. The main goal is to see what dose works best without bad side effects. Participants must be 18 or older, weigh over 50 kg (about 110 pounds), and have a confirmed breast cancer diagnosis, but not inflammatory breast cancer. They should be planning surgery to remove the tumor. Some medical conditions or treatments may prevent joining. The study may involve some risks, like side effects from the drug. There might be no compensation, and the study will need a commitment of time for monitoring after surgery.

• Participants will be involved for at least 14 days after surgery.
• Involves multiple hospital visits for monitoring.
• No financial compensation mentioned.